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Effective Project Management of a  
Pan-African Cancer Research Network: 
Men of African Descent and Carcinoma  
of the Prostate (MADCaP)
INTRODUCTION
Effective health-related research relies on effec-
tive project management to ensure that the 
required tools, techniques, strategies, and sys-
tematic processes have been implemented and 
adhered to to enable the production of quality 
data that can affect disease prevention and con-
trol, as well as policy needs, considering the local 
and national political and social environment.1 
Integrating project management capacity into 
health system–strengthening activities for low- 
and middle-income countries (LMICs) has the 
potential to improve the health of the population 
served2; however, the development and evalua-
tion of the tools and skills for effective project 
management are rarely available in the research 
undertaken in an African setting.3 To achieve 
impactful research in LMICs, there is a need for 
training and education for individuals working at 
all levels, including project managers (PMs), not 
just among high-level research leadership.4
Health research initiatives in LMICs can help fos-
ter capacity building at the local level; however, 
such efforts are often limited to specific, limited 
aims that restrict opportunities to build sustain-
able partnerships and relationships among LMIC 
partners to positively affect health outcomes.3 
Developing project management capacity into 
activities that can broadly strengthen health sys-
tems in LMICs has the potential to improve target 
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organizations’ performance and the health of the 
population served.2 Equally important is moving 
beyond short-term, project-specific objectives 
focused on a particular disease or population to 
envision ways to leverage project resources to 
strengthen the entire health system.5,6
Health research capacity consists of two basic com-
ponents, strategic capacity and operational capac-
ity.7 Strategic capacity in research is defined by 
each project’s specific aims, objectives, research 
questions, and research design. As research proj-
ects are implemented, it is reflected in the ability to 
problem solve and retain fidelity to the stated aims. 
Operational capacity comes from supporting 
project-specific policies and procedures, which 
often include pilot studies and assorted quality 
control checks and may use electronic manage-
ment systems to help track project progress.
Building health research capacity can be achieved 
over time when there is sufficient investment in 
and a commitment to improving practices7; how-
ever, the demands on any contemporary health 
system, whether situated in a high-income coun-
try or an LMIC, often include human and financial 
resource constraints, aging or obsolete infrastruc-
ture, and ever-changing policies and regulations 
striving to accommodate the latest clinical prac-
tice guidelines. To achieve successful research 
output, complex organizations, such as hospitals 
and clinics, must continuously transform and 
adapt to new circumstances. Organizations that 
have this capacity have been dubbed learning 
organizations8 and have comparatively greater 
success in improving their effectiveness and effi-
ciency.9-11 Whereas the concept of cultivating a 
learning organization has been applied in many 
different types of organizations, it is a relatively 
new idea in health systems, particularly in health 
systems that serve LMICs.12
A learning organizational framework lends itself 
to developing management practices that foster 
effectiveness at all levels, appreciating the local 
as well as the global sociocultural context in which 
a given project operates.13,14
Prostate cancer is the leading cancer in Sub- 
Saharan African men, and men of African descent 
have higher prostate cancer frequency, sever-
ity, and death than men of other races, yet little 
is known of its etiology.15 Therefore, dedicated 
resources are needed to try to elucidate the 
causes. Here, we describe a multicenter, inter-
national, hospital-based, case-control study of 
genetic epidemiology of prostate cancer in men 
of African descent and the creation of a project 
manager toolkit (PMT; Table 1).16 This study 
aimed at facilitating the standardization of pro-
tocols and project management for the study, 
with ongoing monitoring and evaluation using 
guidelines recommended by NIH,17,18 as well as 
developing strategic and operational capacity 
for cancer research for each participating cen-
ter. The study, to be conducted over a 5-year 
period, was awarded to the Dana-Farber Cancer 
Institute (T.R., principal investigator [PI]) and the 
Men of African Descent and Carcinoma of the 




The MADCaP research study includes seven par-
ticipating recruitment and implementation cen-
ters (RICs) from four African countries—Nigeria, 
Senegal, Ghana, and South Africa—linked to 
four twinned/mentoring centers (TMCs) located 
in the United States and four central resources 
(CRs) participating as an international team. A 
steering committee and external advisory board 
provided overall oversight and stewardship of 
the MADCaP study (Fig 1). The TMC partner-
ship serves to advise, support, and promote the 
research being conducted at the twinned LMIC 
center, transferring expertise, skills, and knowl-
edge with the goal of establishing a long-term 
collaboration.20
Each RIC identifies and recruits participants with 
prostate cancer and age-matched controls— 
5-year age groups—from local hospitals/clinics, 
collects epidemiologic questionnaires and bio-
specimens (blood or saliva), and performs DNA 
extraction and storage. Eligible participants and 
controls provide data on demographics (Fig 2), 
anthropometrics, physical activity and lifestyle, 
medical history, and family history. Survey data 
are entered with medical record abstracted 
data into a secure database (https://www. 
datstat.com) created for the study. The PMT was 
primarily designed to support these study 
operations.
The Project Manager Working Group (PMWG) 
was formed at the start of the study to support 
the design and implementation of the PMT. The 
PMWG included representation from each RIC, 
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TMC, and CR participating as an international 
team to develop, implement, and evaluate the 
toolkit.
Each RIC was composed of a team that included 
physicians, project managers, research coordi-
nators, phlebotomists, laboratory specialists, 
grant managers, institutional review board man-
agers, database managers, and other study staff 
assembled by the local PI. An electronic survey21 
was conducted to further understand emergent 
patterns of roles and responsibilities under-
taken by RIC staff. A data coordinating center 
was established at the Dana-Farber Cancer 
Institute as a central hub for all data collection, 
processing, quality control, and storage for com-
mon study data. The Centre for Proteomic and 
Genome Research served as a resource for 
facilitating RIC infrastructure to collect biospeci-
mens, perform DNA extractions, conduct quan-
titative and qualitative analyses, and facilitate the 
initial storage of extracted DNA and final ship-
ment to genotyping centers. Using a common 
set of protocols developed for the network, the 
PM at each center was responsible for managing 
the study under guidance and direction of the PI 
to ensure that study objectives, milestones, and 
deliverables were reached.
PMT Development and Implementation Processes
Through an iterative collaborative development 
initiative, standardized protocols, data instru-
ments, and recommended practices were drafted 
and shared across participating centers. PMT 
contents were systematically developed over 
the study’s start-up period, designed to accom-
modate the organizational structure at African 
Sub-Saharan participating study centers (Fig 3), 
and organized to support the key elements of 
study management (Table 1).
The following processes were used to develop 
and implement the PMT:
Timeline charting: A Gantt chart categoriz-
ing important tasks by anticipated start and 
completion times was shared with PMs. 
Adherence to completion times was mon-
itored closely during the study’s start-up 
phase, understanding that challenges to 
keeping to the timeline would vary across 
centers (Data Supplement).
Training: Videos, training manuals, individual 
Web meetings, and in-person group training 
were developed by CR teams.22
Data processing support: To facilitate best 
practices for data entry, management, and 
quality control, a mechanism for electronic 
communication was incorporated into the 
PMT. Guidelines designating responsibility 
for the preparation and sharing of data, pro-
cessing information, frequency of data distri-
bution, and data dissemination were drafted 
and disseminated to PMs and PIs.
Promoting online communication: A Web-
based communications platform,19 built on 
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Table 1. Project Manager Toolkit Contents16
Description Subdescription
Overview and organization 
structure
Participating centers and central resources
Institutions, investigators/project managers, and grant 
administrators






Institutional review board protocol approval
Material transfer agreement
Export/import permit labeling and storage
Study flow diagrams Enrollment and postenrollment processes
Study protocol summary Overview and steps, including eligibility screeners, 
participant identification assignment, biospecimen 
processes
Data collection and study 
forms
Study binder contents with forms
Database management Database user guides
Data management report
Database quality control
Planning, evaluation, and 
follow-up
Milestones, timeline, project scheduling
Quality control/management plan
Enrollment status report
Risk log assessment and follow-up plan (guide)
Communication 
resources/planning
Communications plan and resources
Data access, manuscript, 
grant proposal request 
process
Data usage agreement
Data/project/paper access request form
Authorship guidelines
Project closeout Checklist of all aspects of study close-out undertaken
Appendix Protocol, form, and user guide
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the Alicanto software (http://www.alicanto-
cloud.com), was created for MADCaP net-
work members to help build relationships 
and facilitate timely communication to 
support the development of community of 
practice where participants learn from each 
other and there is a more equal relationship 
between experts and learners, as opposed 
to the traditional model of teachers and stu-
dents.23 It serves as a centralized location 
for all study information, including research 
protocols, instruments, progress reports, 
and research team member profiles, to 
enhance communication strategies. Infor-
mation exchanges took place in person and 
via frequent, coordinated individual center 
and consortia Web conferencing using the 
communications tool, Zoom (https://zoom.us). 
This software works well in low-bandwidth 
conditions and was integrated into the 
platform’s architecture along with calen-
daring capabilities for ease of user project 
activities.
Dissemination and archiving of project man-
agement information: Timely distribution of 
meeting agendas and minutes highlighting 
progress and action items served to doc-
ument study progress. Over time, these 
materials formed an archive that is centrally 
accessible through the MADCaP communi-
cation platform.
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Fig 1. Organizational Chart. Central resources (CRs): Center for Proteomics and Genomics Research, Cape Town, South Africa; Dana-Farber 
Cancer Institute, Boston, MA; Center for Inherited Disease Research and the Intramural Program of the National Cancer Institute, Bethesda, MD. 
Twinning/mentoring centers: Dana-Farber Cancer Institute, Boston, MA; Stanford University, Stanford, CA; Albert Einstein College of Medicine, 
Bronx, NY; Columbia University, New York, NY.
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Site visits: Representatives from TMCs and 
CRs conducted site visits to each RIC to 
evaluate the local context and compliance to 
standardized study protocols and to provide 
guidance and recommendations.
Formation of additional working groups: As 
the study progressed, it became clear that 
additional working groups were needed to 
develop and implement specific study activ-
ities. Protocol and data elements and biospe-
cimen and biobanking working groups were 
established at study initiation to develop, 
standardize, and finalize the protocols and 
data instruments for use in the multicenter 
study. Each RIC undertook a pilot study over 
a defined period to assess the protocols, 
survey delivery, and documenting challenges/
successes encountered. Conducting frequent 
conference calls among RICs provided an 
opportunity to examine and report project 
flow weaknesses/strengths, recording local 
modifications needed for successful study 
implementation. These were shared back to 
the larger group for additional discussion, 
which led to document revisions for use in 
the main study, a core component of the 
PMT, and to ensure comprehensive study 
compliance. Additional working groups were 
established and will continue to form as the 
life cycle of the study moves through different 
phases and additional projects branch off.
RESULTS
Project Management Roles and Responsibilities
Data obtained from conducting the survey of 
project management roles and responsibilities 
helped to further understand emergent patterns 









































































































Fig 2. Population breakdown of the black African cohort enrolled at the African recruitment and implementation centers. Breakdown of ethnicity 
from patients and controls enrolled by the seven recruitment and implementation centers. University of Abuja Teaching Hospital Other category 
includes Afo, Baju, Bini, Busi, Ebira, Ebu, Edo, Ego, Esan, Ewe, Fulani, Gbagyi, Gwandara, Gwari, Idoma, Igala, Ijaw, Ikuku, Ishan, Isoko, Kahoma, 
Koro, Mada, Owhan, Tarok, Tiv, and Ukpela.
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of roles and responsibilities undertaken by RIC 
staff, yielding 51 individual respondents from 
seven centers with varying professional and 
technical backgrounds, which clustered into five 
major categories as follows:
Project management: meeting organization/
calendaring, overall study facilitation, and 
data entry into databases.
Finance and contracts: invoicing and rec-
onciliation, financial management, grant 
administration, and budget development.
Participant recruitment and interviewing: 
subject consent and interview, patient/con-
trol eligibility screening, and form labeling/
storage of participant folders.
Medical record review and abstraction: retrieval 
of paper or electronic patient information.
Biotechnology: phlebotomy and sample label-
ing, biospecimen delivery to the laboratory 
for DNA extraction, quality control measures, 
and storage and shipment of DNA.
Monitoring, Formative Evaluation, and Pilot 
Testing of the PMT
PMs from RICs were asked to share their expe-
riences during the pilot phase of the study, 
describing eligible participants, percent declin-
ing enrollment, number of visits required to 
complete enrollment, challenges encountered, 
and experiences gained (Table 2). Feedback 
from this initial presentation revealed the follow-
ing three focus areas that PMs used to monitor 
progress throughout the research study.
Data quality. Measures were implemented to 
monitor quality, reliability, accuracy, and com-
pleteness of the data being collected and entered 
into the study database to provide a mecha-
nism for feedback to database administrators. 
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Fig 3. Overview of study 
protocol development and 
implementation phases. CR, 
central resource; DUA, data 
use agreement; IRB, insti-
tutional review board; MTA, 
mutual transfer agreement; 
RIC, recruitment and im-
plementation center; TMC, 
twinning/mentoring center. 
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In addition, a comparison between original 
data entry at each RIC and duplicate data entry 
was performed on a subset—10% of random 
samples—of enrolled participants. Second data 
entry was performed by RIC data entry staff 
and results were circulated to CR centers. The 
PM was responsible for receiving discrepancy 
reports and ensuring that differences were 
resolved.
Quality control and management. A quality man-
agement resource plan was established to obtain 
an ongoing assessment of quality indicators.24 
The RIC PM completed sections of this plan 
related to the consent process and signature; 
protocol compliance, form completion, labeling, 
and appropriate storage; biospecimen handling 
and compliance with laboratory protocols; data-
base entry; and institution-specific training and 
training logs.
Project risk assessment and follow-up plan. To 
understand, maintain, and improve performance 
throughout the study lifecycle, this plan25 was 
established as a stepwise process in which risk 
assessment was recorded on a numeric scale 
from 1 to 5. The RIC PM performed an initial 
risk assessment, following standardized guide-
lines, considering the risk impact that each main 
study category might have on the study pro-
cess success action and outcome. Assessment 
of the impact on project risk was scaled from 
1 (minimal) to 5 (very severe), initiating action/
mitigation as needed and designating an individ-
ual to undertake the required task. On subse-
quent assessments, a status category would be 
completed that defined whether the effect had 
been averted, was reducing, or was on the rise 
(Table 3).
Results of the first evaluation conducted by RIC 
PMs using the PMT monitoring and evaluation 
tools during the main study period revealed 
several areas in which challenges existed with 
varying impact factors. The PM tasked a study 
team member to initiate action to achieve an 
improvement plan and solution. These included:
Recruitment/accrual targets: Several centers 
initially fell below their accrual goal. Accrual 
barriers included insufficient eligible par-
ticipants, language barriers, country-wide 
hospital strikes shutting down operations, 
patient costs for obtaining biopsies required 
for eligibility inclusion, delays in sourcing 
necessary diagnostic supplies, and other 
staff/institutional logistics. Solutions included 
extending recruitment to additional hospitals 
and clinics within the catchment area, recruit-
ing interpreters, and increasing communi-
cation channels and relationships between 
hospital and research staff.
Protocol noncompliance: One center reported 
protocol completion noncompliance. One 
participant failed to complete the consent 
process because of time constraints and 
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Table 2. Overview of Challenges and Beneficial Experiences Described by Men of African Descent and Carcinoma of the Prostate Participating 
Centers After Pilot Phase Completion
No. Overall Challenges Described Across Centers
Experiences Gained From the Challenge That Benefited the Enrollment 
Process
1 Trying to engage clinical staff to enable research activities 
in the clinic
Involving senior members of the team to discuss enrollment processes 
with clinical staff
2 Eligible patient or control declining participation Conducting a quick initial health talk on prostate cancer with each 
patient; dissemination of a fact sheet and introductory letter in 
participating departments; the decline rate decreased from 7% in 
patients and 11% in controls at study start to 0% to 1% after pilot 
phase completion
3 Questionnaire length and overall recruitment time needed Increasing study staff and recruitment skills training
4 Empathizing with the physical and emotional state of each 
patient
Flexibility and availability of the research team and clinic staff, and 
exhibiting an empathetic manner toward the patient
5 Language barriers Ensuring that research staff are fluent in the local language
6 Accessibility of patient information and case files Obtaining patient information and case files before the patient’s next 
clinic appointment whenever possible
7 Phlebotomy Having a dedicated phlebotomist available
8 Sourcing research equipment and consumables Processing purchases and orders in advance
9 DNA extraction and storing Training local staff to undertake these processes
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three others declined consent. This center 
found that offering a small token of appre-
ciation of travel vouchers and/or snacks and 
having the caring physician initially introduce 
the study to his patient enhanced protocol 
compliance. One center required multiple 
participant visits to complete enrollment, 
thus maintaining a constant line of commu-
nication with the research participant and 
reminding him of upcoming hospital visits 
via text message enhanced his research 
study participation.
Data management: Two centers experienced 
difficulties initially accessing and navigating 
the online research database, administered 
by DatStat (www.datstat.com). This was 
overcome via focused one-on-one training 
initiatives with the data coordinating center 
and the installation of a remote data collec-
tion module that permitted offline data entry. 
This allowed the center to send or sync col-
lected data to the central online database 
when a stable Internet connection existed.
Metrics were subsequently devised and incor-
porated as reportable factors for the quarterly 
assessment/analytical report of the PMT.26 Main 
study evaluation was subsequently undertaken 
on a quarterly basis with strengthening pro-
cesses initiated for the last 6 months described 
in Table 3.
DISCUSSION
We have described a PMT created expressly to 
support front-line MADCaP local project staff in 
establishing and conducting a multicenter study 
of the genetic epidemiology of prostate cancer 
in African men. PMs need training for the spe-
cific research aims, but to work optimally they 
also need skills and experience in risk analysis, 
setting priorities, planning, budgeting, human 
relations, team building, and incentivizing perfor-
mance.7 The PMT steps away from a top-down 
approach in which donors and external experts 
exclusively inform the study protocol with lim-
ited input from local stakeholders and seeks to 
engage and empower local stakeholders through 
bottom-up strategies that more often help create 
and sustain local organizational capacity.27 To be 
effective, the toolkit guides each organization to 
effectively participate in the study while contin-
ually learning about and adapting to their local 
realities. As a continuous active learning model, 
this PMT guides evaluation phases that will be 
developed, revised, strengthened, and extended 
throughout the project lifecycle. The PMT also 
helps to achieve our aim of enhancing the capac-
ity of MADCaP’s African organizations by empha-
sizing local capacity building from the ground up 
and strengthening center interactions.
Successful research outcomes are dependent 
on the environment and organizational structure 
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Table 3. Evaluation Results and Strengthening Processes Implemented Across RICs Over Two Different Time Points (June and September 2017)
Risk Factor







Lack of patients and/or controls meeting inclusion criteria 4 3 2 4
Patient refusal 2 2 1 4, 5
Inability to age match controls with patients 4 2.5 2 4
Staff operation logistics 3 2.5 2 4, 5
Overall lack of manpower to perform study tasks 2 2 2 4
Medical record inaccessibility 5 2.5 2.5 3, 4
Medical record abstraction completion 3 3 3 4, 5
Phlebotomy/labeling/delivery to laboratory 1 2 1 4, 5
Sourcing of supplies, equipment, and/or reagents 4 3 2 3, 4
Data entry accuracy 1 2 1 4
Communication (in-person meetings) 2 2 2 4
NOTE. RIC No. references the number of African RICs with a specific risk factor. 
Abbreviation: RIC, recruitment and implementation center.
*June 2017 impact of risk factor scoring: 1, minimal; 2, minor; 3, moderate; 4, severe; 5, very severe. 
†September 2018 impact of risk factor scoring: 1, impact averted; 2, impact reducing; 3, impact on the rise.
‡Strengthening action taken (as needed): 1, we have no challenge on this process; 2, we discarded the process; 3, we replaced the process with a new process; 4, we 
improved on the existing process; 5, we retrained the personnel involved in the process; 6, we replaced the personnel involved in the process.
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in which the research study operates. Lack of 
planning, poor quality control, inadequate risk 
management, inefficient organizational structure, 
and breakdowns in communication have been 
associated with long-term project failure.28 Key 
challenges in the project management of multi- 
institutional, multicenter, clinical research studies 
include project team communication, staff train-
ing, efficient and accurate record keeping and 
data integrity, research staff access to clinical 
areas, staff turnover, participant recruitment and 
retention, and navigation of institutional review 
boards and other regulatory bodies.29 Site-specific 
adaptations are also key to a successful outcome, 
particularly when studies are conducted in multiple 
countries. In the current study, one center created 
a cross-center intervention committee to review 
and approve initial protocols, proposing adapta-
tions and the implementation of intervention com-
ponents throughout the study lifecycle. All stages 
of the development of the PMT were the result of 
intensive interaction with the center. This interac-
tion ensured the appropriateness and sustainability 
of its contents to these resource-limited settings. 
Intervention adaptation was essential for scenarios 
that were unforeseen during the design and study 
initiation phases. Such enhancements increased 
the value of the study both locally and globally.
Formative evaluation of the PMT indicates that 
it has fostered the development of both strate-
gic and operational capacity across participating 
study centers. Implementation and preliminary 
use of the PMT monitoring and evaluation module 
permitted the measurement of improvement for 
defined processes that will continue to develop and 
be adapted throughout the project lifecycle. This 
remains essential for all aspects of the study, espe-
cially in developing confidence and rigor toward 
the different tasks and capacity building. Within 
and across centers, the PMT promoted adaptive 
change and accountability, which facilitates proj-
ect success. Through use of the toolkit, common 
expectations and shared understanding about 
goals and objectives led to the dissemination of 
innovative ideas and processes as well as to scaling 
up of effective interventions, which can bring addi-
tional resources for health systems development. 
Where local research capacities are developed, 
improved communication channels and collab-
orative relationships between organizations will 
likely flourish. Specifically, the toolkit is designed to 
ensure regular, timely feedback that supports con-
tinued learning from experience, including learning 
from mistakes and unintended consequences. It is 
also designed to promote accountability. Effective, 
fluid communication, trust building, diplomacy, 
and networking are each critical to achieving proj-
ect outcomes and building local health systems.30
The careful design and implementation of project 
management tools, driven collaboratively by local 
PIs, PMs, and other study stakeholders, using 
continuous evaluation and improvement planning, 
has the potential to ensure successful research 
outcomes and achieve long-term research 
capacity-building goals in LMICs. These successes 
further strengthen the generation of knowledge 
to inform public health needs in LMICs. Effec-
tive implementation of the toolkit described here 
occurred through cycles of dissemination and 
feedback, as facilitated by the PMWG. Investment 
in PM resources is essential for strengthening 
health research outcomes in LMICs.
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